

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-26 (Canceled)

27. (currently amended) A method for treating human subjects with blood clotting disorders, comprising:

administering a pharmaceutical composition to the human subjects,

~~wherein the pharmaceutical composition of claim 26 is administered to human subjects comprising~~  
comprises a peptide of from 3 to 10 amino acids in total length,

wherein said peptide comprises a sequence of between 3 and 10 amino acids which is identical to a sequence of consecutive amino acids found within amino acids 322 to 331 or 352 to 356 of the human blood clotting factor Va (SEQ ID NO. 1), and

wherein the peptide exhibits an IC<sub>50</sub> of between 50 nM to 500  $\mu$ M for inhibition of prothrombinase.

28. (new) The method of claim 27 wherein the peptide comprises at least 5 amino acids which are identical to a sequence of consecutive amino acids found within amino acids 322 to 331 or 352 to 356 of the human blood clotting factor Va (SEQ ID NO. 1).

29. (new) The method of claim 27 wherein the peptide comprises at least 7 amino acids which are identical to a sequence of consecutive amino acids found within amino acids 322 to 331 of the human blood clotting factor Va (SEQ ID NO. 1).

30. (new) The method of claim 27 wherein the peptide comprises at least 10 amino acids which are identical to a sequence of consecutive amino acids found within amino acids 322 to 331 of the human blood clotting factor Va (SEQ ID NO. 1).

31. (new) The method of claim 27, wherein the sequence of then peptide is selected from the group consisting of SEQ ID NO. 6 and SEQ ID NO. 12.

32. (new) The method of claim 27, wherein at least one amino acid within said peptide is a non-naturally occurring amino acid.

33. (new) The method of claim 27, wherein at least one amino acid within said peptide is a D-amino acid.

34. (new) The method of claim 271, wherein at least two amino acids in said sequence are joined by non-hydrolyzable peptide bonds.

Application No.: Not yet assigned  
Preliminary Amendment dated March 8, 2004  
Docket Number: 27433/04016

35. The peptide of claim 1, wherein said peptide is a cyclized peptide.